Back to results
US 10,744,208 B2Granted
Method of attacking target cells
OwnerRobert E. Sandstrominventor
Life of this patent
Estimating the term…
Abstract
A method of killing cells of a targeted cell type in a patient body that utilizes nanoparticles (10) having a first portion (12), which when exposed to a target portion (14) of a targeted cell type (16), binds to the target portion and a second portion (10A), joined to the first portion, and comprised of a low resistivity material. The nanoparticles are introduced into a contact area where they contact cells of the targeted cell type. Contemporaneously, the contact area is exposed to a varying magnetic field of insufficient strength to increase the temperature of any part of the patient body by more than ten degrees Celsius, but which creates a current (20) at the nanoparticles sufficient to disrupt function of the targeted cell type.
Claims30
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, consisting of an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type.
3 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area, consisting of an extracorporeal container, having said patient's blood passing therethrough, where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type.
4 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of the outer cell membrane of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type.
4 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type;
- and
- (d) wherein said method results in an interruption of normal physiologic processes governed by said electrical properties of each said cell of said targeted type, resulting in cell death.
6 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type;
- and
- (d) wherein said method is further accompanied by chemotherapy.
6 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type;
- and
- (d) wherein said method is further accompanied by radiation therapy.
6 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type;
- and
- (d) wherein said method is further accompanied by immunotherapy.
6 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field having a frequency of about 0.6 Hz, and being of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type.
4 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field having a frequency of greater than 0.1 Hz, and being of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type.
4 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field having a magnetic field strength of about 1 Tesla at said contact area, and being of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type.
4 more elements
A method of killing cells of a targeted cell type in a patient, comprising:
- (a) providing nanoparticles having:
- (i) a first portion, of a type taken from a group consisting of:
- an antibody and an aptamer, which when exposed to a target portion of a targeted cell type, binds with specificity to said target portion;
- and
- (ii) a second portion, joined to said first portion, and comprised of a low resistivity material;
- (b) introducing said nanoparticles into a contact area where they can contact said cells of said targeted cell type;
- (c) exposing said contact area to a varying magnetic field that exposes targeted cell types at said contact area to 0.5 V of transmembrane potential, and being of insufficient strength to damage said patient, but which creates a current at said nanoparticles sufficient to disrupt functioning of said targeted cell type.
4 more elements
Dependencies are inferred from the claim text.